FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): Study protocol for randomized controlled trial

Jang Young Kim, Jung Woo Son, Sungha Park, Tea Hyun Yoo, Yong Jin Kim, Dong Ryeol Ryu, Ho Jun Chin

Research output: Contribution to journalArticle

Abstract

Background: Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure (BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes). Methods: This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority, four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with overt proteinuria. Participants will be randomized into four groups (1:1:1:1): fimasartan standard SBP control (SBP<140mmHg); fimasartan strict SBP control (SBP<130mmHg); losartan standard SBP control; and losartan strict SBP control. After 24weeks, all individuals are treated with fimasartan for an additional 120weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The primary endpoint is the rate of change in proteinuria, which is assessed using the spot urine albumin-creatinine ratio at 24weeks. The secondary endpoints are the cardiovascular and renal outcomes at 144weeks compared between the strict SBP and standard SBP control groups. Discussion: The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria. Trial registration: Clinicaltrials.gov, NCT02620306. Registered on 1 December 2015.

Original languageEnglish
Article number632
JournalTrials
Volume18
Issue number1
DOIs
Publication statusPublished - 2017 Dec 29

Fingerprint

Losartan
Diabetic Nephropathies
Chronic Renal Insufficiency
Proteinuria
Randomized Controlled Trials
Blood Pressure
Kidney
Control Groups
Angiotensin Receptor Antagonists
Multicenter Studies
fimasartan
Albumins
Creatinine
Urine
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

@article{274698daae944215a3fa8c37030bac3c,
title = "FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): Study protocol for randomized controlled trial",
abstract = "Background: Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure (BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes). Methods: This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority, four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with overt proteinuria. Participants will be randomized into four groups (1:1:1:1): fimasartan standard SBP control (SBP<140mmHg); fimasartan strict SBP control (SBP<130mmHg); losartan standard SBP control; and losartan strict SBP control. After 24weeks, all individuals are treated with fimasartan for an additional 120weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The primary endpoint is the rate of change in proteinuria, which is assessed using the spot urine albumin-creatinine ratio at 24weeks. The secondary endpoints are the cardiovascular and renal outcomes at 144weeks compared between the strict SBP and standard SBP control groups. Discussion: The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria. Trial registration: Clinicaltrials.gov, NCT02620306. Registered on 1 December 2015.",
author = "Kim, {Jang Young} and Son, {Jung Woo} and Sungha Park and Yoo, {Tea Hyun} and Kim, {Yong Jin} and Ryu, {Dong Ryeol} and Chin, {Ho Jun}",
year = "2017",
month = "12",
day = "29",
doi = "10.1186/s13063-017-2375-8",
language = "English",
volume = "18",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) : Study protocol for randomized controlled trial. / Kim, Jang Young; Son, Jung Woo; Park, Sungha; Yoo, Tea Hyun; Kim, Yong Jin; Ryu, Dong Ryeol; Chin, Ho Jun.

In: Trials, Vol. 18, No. 1, 632, 29.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC)

T2 - Study protocol for randomized controlled trial

AU - Kim, Jang Young

AU - Son, Jung Woo

AU - Park, Sungha

AU - Yoo, Tea Hyun

AU - Kim, Yong Jin

AU - Ryu, Dong Ryeol

AU - Chin, Ho Jun

PY - 2017/12/29

Y1 - 2017/12/29

N2 - Background: Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure (BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes). Methods: This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority, four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with overt proteinuria. Participants will be randomized into four groups (1:1:1:1): fimasartan standard SBP control (SBP<140mmHg); fimasartan strict SBP control (SBP<130mmHg); losartan standard SBP control; and losartan strict SBP control. After 24weeks, all individuals are treated with fimasartan for an additional 120weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The primary endpoint is the rate of change in proteinuria, which is assessed using the spot urine albumin-creatinine ratio at 24weeks. The secondary endpoints are the cardiovascular and renal outcomes at 144weeks compared between the strict SBP and standard SBP control groups. Discussion: The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria. Trial registration: Clinicaltrials.gov, NCT02620306. Registered on 1 December 2015.

AB - Background: Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure (BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes). Methods: This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority, four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with overt proteinuria. Participants will be randomized into four groups (1:1:1:1): fimasartan standard SBP control (SBP<140mmHg); fimasartan strict SBP control (SBP<130mmHg); losartan standard SBP control; and losartan strict SBP control. After 24weeks, all individuals are treated with fimasartan for an additional 120weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The primary endpoint is the rate of change in proteinuria, which is assessed using the spot urine albumin-creatinine ratio at 24weeks. The secondary endpoints are the cardiovascular and renal outcomes at 144weeks compared between the strict SBP and standard SBP control groups. Discussion: The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria. Trial registration: Clinicaltrials.gov, NCT02620306. Registered on 1 December 2015.

UR - http://www.scopus.com/inward/record.url?scp=85039735034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039735034&partnerID=8YFLogxK

U2 - 10.1186/s13063-017-2375-8

DO - 10.1186/s13063-017-2375-8

M3 - Article

C2 - 29284530

AN - SCOPUS:85039735034

VL - 18

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 632

ER -